At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
WTX-330drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients With Advanced or Metastatic Solid Tumors or Lymphoma
In Brief
A Phase 1 clinical trial evaluating WTX-330 for Advanced or Metastatic Solid Tumors and Non-Hodgkin Lymphoma. Completed, enrolled 25 participants across 9 sites.
Detailed Summary
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartDec 2022
First PostedJan 2023
Primary CompletionDec 2024
Study CompletionFeb 2025
TodayJul 2026
First PostedJan 10, 2023
Enrollment StartDec 6, 2022
Primary CompletionDec 23, 2024
Study CompletionFeb 5, 2025
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.5 years ago
Interventions
WTX-330drug
Investigation Product